http://hdl.handle.net/1765/16249

scopus: 63849241865



Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome


Article
volume 113, issue 13 pp 3088-3091.
Related Files
asset icon
(2008120300720.pdf, 0.4MB)

(publisher's version.url.txt, 46 bytes)

Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry 2 mutations (CEBPAdouble-mut), usually biallelic, whereas single heterozygous mutations (CEBPAsingle-mut) are less frequently seen. Using denaturing high-performance liquid chromatography and nucleotide sequencing, we identified among a cohort of 598 newly diagnosed AMLs a subset of 41 CEBPA mutant cases (28 CEBPAdouble-mut and 13 CEBPA single-mut cases) CEBPAdouble-mut associated with a unique gene expression profile as well as favorable overall and event-free survival, retained in multi-variable analysis that included cytoge-netic risk, FZT3-ITD and NPM1 mutation, white blood cell count, and age. In contrast, CEBPA single-mut AMLs did not express a discriminating signature and could not be distinguished from wild-type cases as regards clinical outcome. These results demonstrate significant underlying heterogeneity within CEBPA mutation-positive AML with prognostic relevance.



Keywords


Automatically Extracted Terms
  • mutation
  • cebpa
  • cebpa mutations
  • myeloid leukemia
  • cebpadouble-mut
  • cebpasingle-mut
  • myeloid
  • leukemia
  • expression
  • analysis
  • gene expression
  • blood
  • outcome
  • survival
  • erasmus mc
  • erasmu
  • cebpamut
  • cebpadouble-mut amls
  • figure
  • signi


Bookmark with: